
mAbxience will develop and manufacture the antibody for ONC001, a CD64-targeting ADC aimed at monocytic AML and chronic myelomonocytic leukemia.
How does PAT apply to the bioreactor? Download our comprehensive white paper and explore what PAT means in Biopharma Upstream processes. Discover cutting-edge solutions to effectively monitor critical process parameters and ensure product quality.







